Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2014 5
2015 2
2016 4
2017 6
2018 7
2019 6
2020 4
2021 4
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity.
Choi ML, Chappard A, Singh BP, Maclachlan C, Rodrigues M, Fedotova EI, Berezhnov AV, De S, Peddie CJ, Athauda D, Virdi GS, Zhang W, Evans JR, Wernick AI, Zanjani ZS, Angelova PR, Esteras N, Vinokurov AY, Morris K, Jeacock K, Tosatto L, Little D, Gissen P, Clarke DJ, Kunath T, Collinson L, Klenerman D, Abramov AY, Horrocks MH, Gandhi S. Choi ML, et al. Among authors: athauda d. Nat Neurosci. 2022 Sep;25(9):1134-1148. doi: 10.1038/s41593-022-01140-3. Epub 2022 Aug 30. Nat Neurosci. 2022. PMID: 36042314 Free PMC article.
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Athauda D, et al. Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3. Lancet. 2017. PMID: 28781108 Free PMC article. Clinical Trial.
Diabetes, BMI, and Parkinson's.
Foltynie T, Athauda D. Foltynie T, et al. Among authors: athauda d. Mov Disord. 2020 Feb;35(2):201-203. doi: 10.1002/mds.27941. Mov Disord. 2020. PMID: 32056307 No abstract available.
Drug Repurposing in Parkinson's Disease.
Athauda D, Foltynie T. Athauda D, et al. CNS Drugs. 2018 Aug;32(8):747-761. doi: 10.1007/s40263-018-0548-y. CNS Drugs. 2018. PMID: 30066310 Review.
Amyloid processing in COVID-19-associated neurological syndromes.
Ziff OJ, Ashton NJ, Mehta PR, Brown R, Athauda D, Heaney J, Heslegrave AJ, Benedet AL, Blennow K, Checkley AM, Houlihan CF, Gauthier S, Rosa-Neto P, Fox NC, Schott JM, Zetterberg H, Benjamin LA, Paterson RW. Ziff OJ, et al. Among authors: athauda d. J Neurochem. 2022 Apr;161(2):146-157. doi: 10.1111/jnc.15585. Epub 2022 Mar 2. J Neurochem. 2022. PMID: 35137414 Free PMC article.
Diabetes and Neuroaxonal Damage in Parkinson's Disease.
Vijiaratnam N, Lawton M, Real R, Heslegrave AJ, Guo T, Athauda D, Gandhi S, Girges C, Ben-Shlomo Y, Zetterberg H, Grosset DG, Morris HR, Foltynie T; PRoBaND Clinical Consortium. Vijiaratnam N, et al. Among authors: athauda d. Mov Disord. 2022 Jul;37(7):1568-1569. doi: 10.1002/mds.29067. Mov Disord. 2022. PMID: 35856732 Free PMC article. No abstract available.
43 results